Phase 2 Oesophageal Cancer Trial, Recruiting NCT02584244 Sponsor: Lumicell, Inc. Condition: Oesophageal Cancer
Back to Oesophageal Cancer

Phase 2 Oesophageal Cancer Trial, Recruiting

NCT02584244
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been confirmed through a tissue sample (biopsy) to have a type of cancer called adenocarcinoma (or a related condition) in the esophagus, colon/rectum, or pancreas, and you are scheduled to have surgery or a procedure to remove the tumor.
  • You are at any stage of cancer — early or advanced stages are both included.
  • You may have already received chemotherapy or radiation therapy before surgery.
  • You are 18 years of age or older.
  • You are willing and able to follow the study's instructions and procedures.
  • You have signed a consent form agreeing to take part.
  • You are healthy enough to undergo surgery or a procedure performed with a camera scope.
  • Your blood test results show that your immune cells, blood clotting cells, liver, and kidneys are working within acceptable ranges (confirm with trial site for exact numbers).
  • You are generally fit and able to carry out daily activities with no more than mild limitations (confirm with trial site).
  • If you are a woman who could become pregnant, you agree to use reliable birth control starting from when you join the study and for 60 days after receiving the study imaging agent.

Who may not be able to join:

  • You have taken an experimental drug within the last 30 days.
  • You have an irregular heart rhythm of a specific type detected on a heart tracing test (confirm with trial site).
  • You are still experiencing side effects from a medication or medical test given more than 4 weeks ago.
  • You have uncontrolled high blood pressure that remains very elevated even with medication.
  • You have had an allergic reaction to products containing polyethylene glycol (PEG), a substance found in some medicines and products.
  • You have had an allergic reaction to contrast dyes used in scans or X-rays.
  • You are pregnant or currently breastfeeding.
  • You are sexually active but unwilling or unable to use an acceptable form of contraception during the study.
  • You are HIV-positive and taking combination anti-HIV medications.
  • The trial doctor believes that joining the study would not be in your best interest for any reason.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 2 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Lumicell, Inc.
Registry
ClinicalTrials.gov
Start date
4 August 2016
Est. completion
1 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Correlate LUM015 fluorescence in gastrointestinal cancers (pancreatic, esophageal, and colorectal) with pathology results

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov